Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes? Response

被引：0
|
作者：
Bennett, Melanie E. [1 ]
Calkins, Monica E. [2 ,3 ]
Dickerson, Faith [4 ]
Kreyenbuhl, Julie [1 ]
Medoff, Deborah [1 ]
机构：
[1] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD USA
[2] Univ Penn, Perelman Sch Med, Penn Early Intervent Ctr PE HeadsUp, Dept Psychiat,Neurodev & Psychosis Sect, Philadelphia, PA USA
[3] Univ Penn, Perelman Sch Med, Dept Psychiat, Neurodev & Psychosis Sect, Philadelphia, PA USA
[4] Sheppard Pratt, Dept Psychol, Baltimore, MD USA
来源：
SCHIZOPHRENIA RESEARCH | 2024年 / 270卷
关键词：
D O I：
10.1016/j.schres.2024.06.012
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [31] Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study
    Lee, Su Jin
    Ha, Kyoung Hwa
    Lee, Jung Hyun
    Lee, Hokyou
    Kim, Dae Jung
    Kim, Hyeon Chang
    PLOS ONE, 2019, 14 (02):
  • [32] Mechanisms of glucose-lowering effect by rosiglitazone in patients with type 2 diabetes
    Miyazaki, Y
    Matsuda, M
    Mahankali, A
    Mahankali, S
    Cusi, K
    Mandarino, L
    Defronzo, R
    DIABETES, 2001, 50 : A126 - A127
  • [33] Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
    Prattichizzo, Francesco
    La Sala, Lucia
    Ryden, Lars
    Marx, Nikolaus
    Ferrini, Marc
    Valensi, Paul
    Ceriello, Antonio
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (2_SUPPL) : 73 - 80
  • [34] Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
    Schernthaner, Guntram
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (05): : 251 - 252
  • [35] Glucose-lowering effects of sulfasalazine in type 2 diabetes
    Haas, RM
    Li, P
    Chu, JW
    DIABETES CARE, 2005, 28 (09) : 2238 - 2239
  • [36] Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study
    Rathmann, Wolfgang
    Charbonnel, Bernard
    Gomes, Marilia B.
    Hammar, Niklas
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Kuss, Oliver
    Shestakova, Marina V.
    Watada, Hirotaka
    Shimomura, Iichiro
    Tang, Fengming
    Cid-Ruzafa, Javier
    Chen, Hungta
    Fenici, Peter
    Surmont, Filip
    Ji, Linong
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 165
  • [37] Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk
    Htoo, Phyo T.
    Paik, Julie M.
    Alt, Ethan
    Kim, Dae Hyun
    Wexler, Deborah J.
    Kim, Seoyoung C.
    Patorno, Elisabetta
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2023, 78 (12): : 2426 - 2434
  • [38] Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective
    Thompson, Peter L.
    Davis, Timothy M. E.
    CLINICAL THERAPEUTICS, 2017, 39 (05) : 1012 - 1025
  • [39] Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
    Kristina S. Boye
    Reema Mody
    Maureen J. Lage
    Steven Douglas
    Hiren Patel
    Diabetes Therapy, 2020, 11 : 1513 - 1525
  • [40] Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
    Boye, Kristina S.
    Mody, Reema
    Lage, Maureen J.
    Douglas, Steven
    Patel, Hiren
    DIABETES THERAPY, 2020, 11 (07) : 1513 - 1525
12345